Cantor Fitzgerald sets GH Research stock Overweight, $14 target
GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...
GH Research initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan initiated coverage of GH Research (GHRS) with an Overweight rating and no price target GH Research is ...
‘I’m just a seeker’: The Sydney mum who spent a year sampling psychedelics
Sarah Napthali lowers her voice over lunch when our conversation veers to the names of the drugs she used: LSD, MDMA, ...
BioWorld12d
Compass points true north for GH’s phase IIb depression trial
Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
BioSpace12d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...
Veteran faces childhood trauma on psychedelic journey
Navy veteran Michael Giardina told Anderson Cooper he was able to "let go" of trauma from his childhood during a psychedelic ...
Seeking Alpha17d
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
This synthetic intranasal formulation of 5-MeO-DMT benzoate is designed to deliver a durable treatment option to AUD and other psychiatric disorders. The drug, along with relapse prevention ...
Atai reports positive data for psychedelic drug BPL-003
Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...
BioSpace19d
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
BPL-003 is an intranasal formulation of 5-MeO-DMT benzoate being developed by Beckley Psytech, in which atai holds a 35.5% equity interest. In the Phase IIa study, treatment with BPL-003 combined with ...